Preclinical Drug Metabolism Programs for Food-Producing Animals

Abstract

To register a new veterinary drug for use in food-producing animals, the sponsor must demonstrate that drug-related residues in the edible tissues (liver, kidneys, muscle, fat, and milk or eggs) of treated animals are safe when consumed by humans. The sponsor must develop information on the amount, persistence, and chemical nature of the drug-derived residue in the edible tissues in order to ensure safety. This information is compared to that on the metabolism and toxicity of the compound in the laboratory animal species used for the toxicity evaluation. The toxicity data is utilized to establish the safe concentration of drug-related residue in the edible tissues. An estimate of the safe concentration is necessary to proceed with residue studies that will adequately determine the rate of depletion of total residue over the projected range of probable safe concentrations. Appropriate study design requires close communication among the toxicologist, pathologist, and residue chemist. The safe concentration of total residue and residue depletion profile are used to determine the withdrawal period for the veterinary product. The required studies, including design and timing, will be discussed.

Keywords

Residue tissue veterinary depletion withdrawal

References

Center for Veterinary Medicine, Guideline Number 3 (July 1994). Part I: Guideline for metabolism studies and for selection of residues for toxicological testing. In: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Washington, D.C., p. 1-1.

Center for Veterinary Medicine, Guideline Number 3 (Revised July 1994). General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals. Guidelines I-VIII . U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Washington, D.C.

Center for Veterinary Medicine, Guideline Number 3 (July 1994). Part VI: Guideline for establishing a withdrawal period. In: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Washington, D.C., pp. VI-2-VI-7.

Center for Veterinary Medicine, Guideline Number 3 (July 1994). Part IV: Guideline for establishing a safe concentration. In: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration , Washington, D.C., pp. IV-1-VI-2.

Commission of the European Communities (January 1993). Part III: Safety and residues documentation . In: The Rules Governing Medicinal Products in the European Community, Vol. VB. Directorate-General for Internal Market and Industrial Affairs, Brussels, pp. 95-100.

O'Kennedy M. (1990). Council Regulation (EEC) No. 2377/90, Article 1. Official Journal of the European Communities, Brussels, No. L224: 2.